Get started
Author

Priya Mehta

Observed name: Dr. Priya Mehta
ORCID: 0000-0002-0886-9670
Observed ORCID: 0000-0002-0886-9670
OpenAlex ID: A5091899951
Addition of trastuzumab emtansine (T-DM1) in a human epidermal growth factor receptor 2–overexpressed metastatic carcinoma of the gallbladder patient to enhance survival: A case study
2022 · Viraj Lavingia, Vipulkumar Thummar, et al. · SAGE Open Medical Case Reports · 5
Favorable Outcome and Safety of Neoadjuvant Trastuzumab Emtansine (T-DM1) in a HER2-Positive Early Breast Cancer Patient with Severe Renal Disease on Hemodialysis Ineligible for Conventional Chemotherapy: A Case Report
2023 · Suman Kalyan Natarajan, Joice Crystal Danansezhian, et al. · Reports — Medical Cases Images and Videos · 3
PDF
Real-World Evaluation of a Trastuzumab Emtansine Biosimilar (Ujvira®) in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
2026 · MV Chandrakanth, Vivek Agarwala, et al. · Cureus · 2
PDF
Evaluation of the Safety and Efficacy of Trastuzumab Emtansine (T-DM1) Biosimilar in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer: Findings From a Single-Center Retrospective Analysis in India
2024 · Kaushal Patel, Vipulkumar Thummar, et al. · Cureus · 2
PDF
Real-World Evaluation of Trastuzumab Emtansine Biosimilar in Early-Stage HER2-Positive Breast Cancer: Results from a Single-Center Retrospective Study in India
2026 · Kaushal Kaushal, Vipulkumar Thummar, et al. · Archives of Breast Cancer · 1
PDF
Real‐World Safety and Efficacy of Biosimilar Trastuzumab Emtansine (T‐DM1) in HER2‐Positive Breast Cancer: A Prospective Single‐Institution Study From India
2026 · Divya Gandrala, Senthil J. Rajappa, et al. · International Journal of Breast Cancer · 1
A Case Report on Trastuzumab Emtansine (T-DM1) in a Patient With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer and Brain Metastases: Long-Term Treatment and Survival
2024 · Vipul Doshi, Vipulkumar Thummar, et al. · Cureus · 1
PDF
Sequential Anti-HER2 (Human Epidermal Growth Factor Receptor 2) Therapy and Late-Line Tucatinib in Patients With HER2-Positive Breast Cancer and Brain Metastases: A Real-World Case Report
2026 · Purnima Thakur, Manish Gupta, et al. · Cureus
PDF
Clinical outcomes of neoadjuvant dual HER2 blockade with pertuzumab/Sigrima and trastuzumab/Vivitra biosimilars: real-world evidence in HER2-positive breast cancer in India
2026 · Priya Mehta, Vipulkumar Thummar, et al. · International Journal of Research in Medical Sciences
PDF
Clinical Response to T-DM1 Plus Tucatinib in Pre-treated HER2-Positive Metastatic Breast Cancer: A Case Series.
2026 · Dr. Chandrakanth MV, Dr. Vivek Agarwala, et al. · Archives of Clinical and Medical Case Reports
PDF
Nab-Paclitaxel-Based Systemic Approach to Achieving Complete Remission for Relapsed Stage III Endometrial Carcinoma: Insights From the Indian Subcontinent
2024 · Prasanna Rammohan, Vipulkumar Thummar, et al. · Cureus
PDF
A Case Report on Prolonged Response with Trastuzumab Emtansine (T-DM1) in Recurrent Advance Breast Cancer Setting
2023 · Praneet Singh Bedi, Meenu Walia, et al. · Journal of cancer research updates
PDF
A Case Report on the Efficacy of Trastuzumab Emtansine in a Patient With Human Epidermal Growth Factor Receptor 2 Exon 20-Mutated Adenocarcinoma of the Lung
2023 · Arun Warrier, Anu George, et al. · Cureus
PDF
Works count: 13
Citation count: 15
H-index: 2
I10-index:
Year
Topic
Type